Country exposure

as of 11 Dec 2019 (%)

Sector exposure

as of 11 Dec 2019 (%)

Top 10 Exposures as of 11 Dec 2019 (%)

Name ISIN Weight
ARROWHEAD PHARMACEUTICALS ORD US04280A1007 0.85%
MEDICINES ORD US5846881051 0.81%
DARLING INGREDIENTS ORD US2372661015 0.53%
LHC GROUP ORD US50187A1079 0.51%
TOPBUILD ORD US89055F1030 0.49%
RH ORD US74967X1037 0.49%
GLACIER BANCORP ORD US37637Q1058 0.49%
LITHIA MOTORS CL A ORD US5367971034 0.47%
JOHN BEAN TECHNOLOGIES ORD US4778391049 0.46%
NEOGEN ORD US6404911066 0.46%

Key information

Bloomberg ticker USML LN
ISIN IE00BH3YZ803
Benchmark BBG ticker SPTRSMCN
Management fee 0.14%
Swap fee 0.00%
NAV (11 Dec 2019) $43.58
AUM $13,118,169
Base currency USD

Key Risks

Counterparty Risk: Other financial institutions provide services such as safekeeping of assets or as a counterparty to financial contracts such as derivatives. The Fund is exposed to the risk of bankruptcy, or any other type of default of the counterparty related to any trading transaction entered into by the Fund.

Risk of using Derivatives: in order to reach its investment objective, the Fund enters into swap agreements which provide the performance of the Index, and may imply a range of risks which could lead to an adjustment or even the early termination of the swap agreement.

Liquidity on secondary market risk: As the shares of the Fund are listed on one or more stock exchange(s) there may be insufficient demand to buy or sell the shares which may cause the price to be different than the actual value of the net asset value of the Fund.

Equity Risk: Shares of companies are generally considered high risk investments and may result in fluctuations in the value of the Fund due to external factors.

 

The performance information on this web page refers to past performance. Past performance is not a reliable indicator of future returns.

The data shown on this page is not real-time, i.e. it may be delayed due to mandatory requirements of the data provider. As a consequence, the price of the product linked to a specific underlying you are quoted by your broker or intermediary may substantially differ from the price of the product that you would expect on the basis of the data displayed on this site. Invesco accepts no responsibility for loss, however caused, resulting from errors in this data.

ETF performance is in the fund’s base currency, includes dividends, reinvested. ETF performance is Net Asset Value after management fees and other ETF costs but does not consider any commissions or custody fees payable when buying, holding or selling the ETF. The ETF does not charge entry or exit fees. Data: Invesco.